Serum MFAP4 had a high NPV for advanced fibrosis and cirrhosis (91% and 97% respectively) and a moderate PPV (74% for advanced fibrosis and 58% for cirrhosis) in the training cohort. The gene discussed is MFAP4; the disease is fibrosis.